Modified Aerotaxy for the Plug-in Manufacture of Cell-Penetrating Fenton Nanoagents for Reinforcing Chemodynamic Cancer Therapy

被引:6
|
作者
Poudel, Kishwor [1 ,2 ]
Nam, Kang Sik [3 ]
Lim, Jiseok [5 ]
Ku, Sae Kwang [4 ]
Hwang, Jungho [3 ]
Kim, Jong Oh [1 ]
Byeon, Jeong Hoon [5 ]
机构
[1] Yeungnam Univ, Coll Pharm, Gyongsan 38541, South Korea
[2] Meassachusetts Gen Hosp, Wellman Ctr Photomed, Harvard Med Sch, Dept Dermatol, Boston, MA 02114 USA
[3] Yonsei Univ, Sch Mech Engn, Seoul 03722, South Korea
[4] Daegu Haany Univ, Coll Korean Med, Gyongsan 38610, South Korea
[5] Yeungnam Univ, Sch Mech Engn, Gyongsan 38541, South Korea
基金
新加坡国家研究基金会;
关键词
anisotropic nanomaterials; modified aerotaxy; Fenton nanoagents; cellular internalization; chemo-immuno-chemodynamic combination therapeutics; MESOPOROUS SILICA NANOPARTICLES; MNFE2O4; NANOPARTICLES; FACILE SYNTHESIS; COMBINATION; DOXORUBICIN; DEPOSITION; RESISTANCE; MORPHOLOGY; EXPRESSION; NANOWIRES;
D O I
10.1021/acsnano.2c09136
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The assemblies of anisotropic nanomaterials have attracted considerable interest in advanced tumor therapeutics because of the extended surfaces for loading of active molecules and the extraordinary responses to external stimuli for combinatorial therapies. These nanomaterials were usually constructed through templated or seed-mediated hydrothermal reactions, but the lack of uniformity in size and morphology, as well as the process complexities from multiple separation and purification steps, impede their practical use in cancer nanotherapy. Gas-phase epitaxy, also called aerotaxy (AT), has been introduced as an innovative method for the continuous assembly of anisotropic nanomaterials with a uniform distribution. This process does not require expensive crystal substrates and high vacuum conditions. Nevertheless, AT has been used limitedly to build high-aspect-ratio semiconductor nanomaterials. With these considerations, a modified AT was designed for the continuous in-flight assembly of the cell-penetrating Fenton nanoagents (Mn-Fe CaCO3 (AT) and Mn-Fe SiO2 (AT)) in a single-pass gas flow because cellular internalization activity is essential for cancer nanotherapeutics. The modified AT of Mn-Fe CaCO3 and Mn-Fe SiO2 to generate surface nanoroughness significantly enhanced the cellular internalization capability because of the preferential contact mode with the cancer cell membrane for Fenton reaction-induced apoptosis. In addition, it was even workable for doxorubicin (DOX)-resistant cancer cells after DOX loading on the nanoagents. After combining with immune-checkpoint blockers (antiprogrammed death-ligand 1 antibodies), the antitumor effect was improved further with no systemic toxicity as chemo-immuno-chemodynamic combination therapeutics despite the absence of targeting ligands and external stimuli.
引用
收藏
页码:19423 / 19438
页数:16
相关论文
共 36 条
  • [11] Thermosensitive magnetic liposomes with doxorubicin cell-penetrating peptides conjugate for enhanced and targeted cancer therapy
    Lin, Wen
    Xie, Xiangyang
    Yang, Yanfang
    Fu, Xudong
    Liu, Hong
    Yang, Yang
    Deng, Jianping
    DRUG DELIVERY, 2016, 23 (09) : 3436 - 3443
  • [12] Cell-Penetrating Peptide-Modified Gold Nanoparticles for the Delivery of Doxorubicin to Brain Metastatic Breast Cancer
    Morshed, Ramin A.
    Muroski, Megan E.
    Dai, Qing
    Wegscheid, Michelle L.
    Auffinger, Brenda
    Yu, Dou
    Han, Yu
    Zhang, Lingjiao
    Wu, Meijing
    Cheng, Yu
    Lesniak, Maciej S.
    MOLECULAR PHARMACEUTICS, 2016, 13 (06) : 1843 - 1854
  • [13] Cell-Penetrating Peptides as a Tool for the Cellular Uptake of a Genetically Modified Nitroreductase for use in Directed Enzyme Prodrug Therapy
    Anderson, Simon D.
    Hobbs, Robert J.
    Gwenin, Vanessa V.
    Ball, Patrick
    Bennie, Lindsey A.
    Coulter, Jonathan A.
    Gwenin, Chris D.
    JOURNAL OF FUNCTIONAL BIOMATERIALS, 2019, 10 (04)
  • [14] Enhancing siRNA-based cancer therapy using a new pH-responsive activatable cell-penetrating peptide-modified liposomal system
    Xiang, Bai
    Jia, Xue-Li
    Qi, Jin-Long
    Yang, Li-Ping
    Sun, Wei-Hong
    Yan, Xiao
    Yang, Shao-Kun
    Cao, De-Ying
    Du, Qing
    Qi, Xian-Rong
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2017, 12 : 2385 - 2405
  • [15] Targeted Delivery of Cabazitaxel Using Cyclic Cell-Penetrating Peptide and Biomarkers of Extracellular Matrix for Prostate and Breast Cancer Therapy
    Park, Shang Eun
    El-Sayed, Naglaa Salem
    Shamloo, Kiumars
    Lohan, Sandeep
    Kumar, Sumit
    Sajid, Muhammad Imran
    Tiwari, Rakesh Kumar
    BIOCONJUGATE CHEMISTRY, 2021, 32 (08) : 1898 - 1914
  • [16] Protease-activatable cell-penetrating peptide possessing ROS-triggered phase transition for enhanced cancer therapy
    Yoo, Jisang
    Rejinold, N. Sanoj
    Lee, DaeYong
    Jon, Sangyong
    Kim, Yeu-Chun
    JOURNAL OF CONTROLLED RELEASE, 2017, 264 : 89 - 101
  • [17] Development of cell-penetrating bispecific antibodies targeting the N-terminal domain of androgen receptor for prostate cancer therapy
    Goicochea, Nancy L.
    Garnovskaya, Maria
    Blanton, Mary G.
    Chan, Grace
    Weisbart, Richard
    Lilly, Michael B.
    PROTEIN ENGINEERING DESIGN & SELECTION, 2017, 30 (12): : 785 - 793
  • [18] A Cell-Penetrating Peptide Modified Cu2-xSe/Au Nanohybrid with Enhanced Efficacy for Combined Radio-Photothermal Therapy
    Ran, Ruixue
    Guo, Sinan
    Jiang, Xiaoyu
    Qian, Zhanyin
    Guo, Zhaoyang
    Wang, Yinsong
    Cao, Mingxin
    Yang, Xiaoying
    MOLECULES, 2023, 28 (01):
  • [19] Cell-Penetrating and Enzyme-Responsive Peptides for Targeted Cancer Therapy: Role of Arginine Residue Length on Cell Penetration and In Vivo Systemic Toxicity
    Ghaemi, Behnaz
    Tanwar, Swati
    Singh, Aruna
    Arifin, Dian R.
    Mcmahon, Michael T.
    Barman, Ishan
    Bulte, Jeff W. M.
    ACS APPLIED MATERIALS & INTERFACES, 2024, 16 (09) : 11159 - 11171
  • [20] Cell-Penetrating Apoptotic Peptide/p53 DNA Nanocomplex as Adjuvant Therapy for Drug-Resistant Breast Cancer
    Wang, Huiyuan
    Wang, Huixin
    Liang, Jianming
    Jiang, Yifan
    Guo, Qianqian
    Peng, Huige
    Xu, Qin
    Huang, Yongzhuo
    MOLECULAR PHARMACEUTICS, 2014, 11 (10) : 3352 - 3360